BDX Quote, Financials, Valuation and Earnings

Baxter International has a net margin of 5.86% compared to Becton Dickinson &'s net margin of -18.6%. Becton Dickinson &'s return on equity of 6.75% beat Baxter International's return on equity of -8.24%.

Becton Dickinson & has a consensus price target of $275.03, signalling upside risk potential of 33.7%. On the other hand Baxter International has an analysts' consensus of $39.74 which suggests that it could grow by 40.03%. Given that Baxter International has higher upside potential than Becton Dickinson &, analysts believe Baxter International is more attractive than Becton Dickinson &.

Becton Dickinson & has a beta of 0.349, which suggesting that the stock is 65.131% less volatile than S&P 500. In comparison Baxter International has a beta of 0.645, suggesting its less volatile than the S&P 500 by 35.462%.

Becton Dickinson & has a quarterly dividend of $1.04 per share corresponding to a yield of 1.94%. Baxter International offers a yield of 3.24% to investors and pays a quarterly dividend of $0.17 per share. Becton Dickinson & pays 64.52% of its earnings as a dividend. Baxter International pays out -90.91% of its earnings as a dividend. Becton Dickinson &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Becton Dickinson & quarterly revenues are $5.2B, which are larger than Baxter International quarterly revenues of $2.8B. Becton Dickinson &'s net income of $303M is higher than Baxter International's net income of -$512M. Notably, Becton Dickinson &'s price-to-earnings ratio is 34.17x while Baxter International's PE ratio is 167.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Becton Dickinson & is 2.90x versus 1.13x for Baxter International. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific has a net margin of 5.86% compared to Becton Dickinson &'s net margin of 12.41%. Becton Dickinson &'s return on equity of 6.75% beat Boston Scientific's return on equity of 8.96%.

Becton Dickinson & has a consensus price target of $275.03, signalling upside risk potential of 33.7%. On the other hand Boston Scientific has an analysts' consensus of $115.00 which suggests that it could grow by 21.99%. Given that Becton Dickinson & has higher upside potential than Boston Scientific, analysts believe Becton Dickinson & is more attractive than Boston Scientific.

Becton Dickinson & has a beta of 0.349, which suggesting that the stock is 65.131% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.728, suggesting its less volatile than the S&P 500 by 27.188%.

Becton Dickinson & has a quarterly dividend of $1.04 per share corresponding to a yield of 1.94%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Becton Dickinson & pays 64.52% of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend. Becton Dickinson &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Becton Dickinson & quarterly revenues are $5.2B, which are larger than Boston Scientific quarterly revenues of $4.6B. Becton Dickinson &'s net income of $303M is lower than Boston Scientific's net income of $566M. Notably, Becton Dickinson &'s price-to-earnings ratio is 34.17x while Boston Scientific's PE ratio is 75.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Becton Dickinson & is 2.90x versus 8.36x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of 5.86% compared to Becton Dickinson &'s net margin of 26.88%. Becton Dickinson &'s return on equity of 6.75% beat ResMed's return on equity of 25.56%.

Becton Dickinson & has a consensus price target of $275.03, signalling upside risk potential of 33.7%. On the other hand ResMed has an analysts' consensus of $267.15 which suggests that it could grow by 24.53%. Given that Becton Dickinson & has higher upside potential than ResMed, analysts believe Becton Dickinson & is more attractive than ResMed.

Becton Dickinson & has a beta of 0.349, which suggesting that the stock is 65.131% less volatile than S&P 500. In comparison ResMed has a beta of 0.755, suggesting its less volatile than the S&P 500 by 24.514%.

Becton Dickinson & has a quarterly dividend of $1.04 per share corresponding to a yield of 1.94%. ResMed offers a yield of 0.97% to investors and pays a quarterly dividend of $0.53 per share. Becton Dickinson & pays 64.52% of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Becton Dickinson & quarterly revenues are $5.2B, which are larger than ResMed quarterly revenues of $1.3B. Becton Dickinson &'s net income of $303M is lower than ResMed's net income of $344.6M. Notably, Becton Dickinson &'s price-to-earnings ratio is 34.17x while ResMed's PE ratio is 25.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Becton Dickinson & is 2.90x versus 6.42x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.

Stryker has a net margin of 5.86% compared to Becton Dickinson &'s net margin of 8.48%. Becton Dickinson &'s return on equity of 6.75% beat Stryker's return on equity of 15.22%.

Becton Dickinson & has a consensus price target of $275.03, signalling upside risk potential of 33.7%. On the other hand Stryker has an analysts' consensus of $421.86 which suggests that it could grow by 19.37%. Given that Becton Dickinson & has higher upside potential than Stryker, analysts believe Becton Dickinson & is more attractive than Stryker.

Becton Dickinson & has a beta of 0.349, which suggesting that the stock is 65.131% less volatile than S&P 500. In comparison Stryker has a beta of 0.929, suggesting its less volatile than the S&P 500 by 7.107%.

Becton Dickinson & has a quarterly dividend of $1.04 per share corresponding to a yield of 1.94%. Stryker offers a yield of 0.93% to investors and pays a quarterly dividend of $0.84 per share. Becton Dickinson & pays 64.52% of its earnings as a dividend. Stryker pays out 40.73% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Becton Dickinson & quarterly revenues are $5.2B, which are smaller than Stryker quarterly revenues of $6.4B. Becton Dickinson &'s net income of $303M is lower than Stryker's net income of $546M. Notably, Becton Dickinson &'s price-to-earnings ratio is 34.17x while Stryker's PE ratio is 45.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Becton Dickinson & is 2.90x versus 6.03x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.